The company have significantly improved its check here progress of the novel treatment for cardiac amyloidosis, employing the compound. Early patient data suggests significant outcomes for patients affected by a severe condition. This effort highlights BridgeBio's focus to addressing significant patient demands in this cardiology field. Attruby: B